The rising demand for liquid biopsies for cancer detection is expected to boost the demand for circulating tumor cell diagnostics. Leading market players focus on enlarging their reach across emerging markets by expanding their distribution networks and augmenting manufacturing capabilities. Emerging markets in India and South Korea are expected to offer potential growth opportunities for crucial circulating tumor cell (CTC) diagnostics market players in the coming years. This can be attributed to the large patient population, high cancer prevalence (including types such as skin, breasts, lungs, pancreas, and other organs and glands), increasing disposable income, improving healthcare infrastructure, and growing medical tourism in these countries. As the markets mature, most players are shifting their focus to emerging markets. High investments in life science and health research in emerging countries play a key role in upgrading their healthcare infrastructure with the latest technologies. This factor, in turn, supports the progress in cancer diagnostics, thereby creating new opportunities for the Asia Pacific circulating tumor cell (CTC) diagnostics market players.
Prohibitive measures have been taken to contain the spread of the COVID-19 pandemic in APAC countries. The pandemic has largely affected the economies of India, China, Japan, and South Korea, among others. The onset of the pandemic and exponential rise in patients with the need of hospitalization led to delays and temporary suspension of cancer screening, diagnosis, and treatment services. Moreover, government regulations, nationwide lockdowns, and spiking infection rates had a significant financial impact on healthcare facilities. Several hospitals and clinics have seen a decrease in patient visits as a result of COVID-19. The scarcity of medical care and supplies for conditions other than COVID-19 had a detrimental impact on the circulating tumor cell diagnostics market proliferation. At the same time, limited healthcare staff availability hampered the circulating tumor cell diagnostics market in Asia Pacific. In addition, the socio-economy was badly hit, with growing inflation, declining GDP, and rising unemployment in the region. The pandemic has affected three main aspects of the global economy: manufacturing, supply chain, and business and financial markets.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the circulating tumor cell (CTC) diagnostics market. The Asia Pacific circulating tumor cell (CTC) diagnostics market is expected to grow at a good CAGR during the forecast period.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 347.6 Million |
| Market Size by 2028 | US$ 689.3 Million |
| CAGR (2021 - 2028) | 10.3% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Technology
|
|
Regions and Countries Covered
|
|
| Asia-Pacific | China, India, Japan, Australia, Rest of Asia-Pacific |
| Market leaders and key company profiles |
|
The Asia Pacific Circulating Tumor Cell (CTC) Diagnostics Market is valued at US$ 347.6 Million in 2021, it is projected to reach US$ 689.3 Million by 2028.
As per our report Asia Pacific Circulating Tumor Cell (CTC) Diagnostics Market, the market size is valued at US$ 347.6 Million in 2021, projecting it to reach US$ 689.3 Million by 2028. This translates to a CAGR of approximately 10.3% during the forecast period.
The Asia Pacific Circulating Tumor Cell (CTC) Diagnostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Circulating Tumor Cell (CTC) Diagnostics Market report:
The Asia Pacific Circulating Tumor Cell (CTC) Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Circulating Tumor Cell (CTC) Diagnostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Circulating Tumor Cell (CTC) Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Circulating Tumor Cell (CTC) Diagnostics Market
